Dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: results from the VISION trial sub-study. This is an ASCO Meeting Abstract from the 2022 ASCO ...
The role of highly selective androgen receptor (AR) targeted therapy in men with biochemically relapsed hormone sensitive prostate cancer. This is an ASCO Meeting Abstract from the 2015 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results